Vancouver, British Columbia – July 14th, 2025 – Rackla Metals Inc. (TSX-V: RAK) is pleased to announce that drilling and has commenced at the BiTe zone on the Grad property NWT. The Grad property was staked in July of 2024, and immediate prospecting defined strong gold mineralization at the base of the south facing cliff.  Further sampling in August identified significant sheeted veining hosted in the intrusive and that combined with the gold, bismuth and tellurium geochemistry made it clear that we had di ...

Group 1 - The recent wave of closures among retail and dining establishments in Hong Kong, including long-established restaurants, has raised societal concerns, leading to the term "closure wave" being used [1] - Despite some closures, new establishments are opening, indicating a dynamic market that requires a rational perspective on the situation [1] - The opening of a new 24-hour branch of the century-old tea house "Lin Heung Tea House" in Tsim Sha Tsui and the entry of mainland brands like "Da Rong Shu Xia" reflect confidence in the Hong Kong market [3] Group 2 - In May, Hong Kong's retail sales increased by 2.4% year-on-year, ending a 14-month decline, with both local and non-local companies reaching record numbers [3] - The expected economic growth for Hong Kong this year is between 2% and 3%, indicating a positive trend in the economy and business environment [3] - The transformation of market supply and demand, along with changing consumer patterns, is impacting traditional businesses, necessitating adaptation and innovation [4] Group 3 - The Hong Kong government has introduced measures to assist small and medium-sized enterprises (SMEs) during the transition period, including a dedicated fund for market expansion and digital upgrades [5] - The "Hong Kong Good Goods Festival" has been launched to support SMEs in developing e-commerce, with reports of significant revenue increases for participating businesses [5] - Continuous innovation and willingness to adapt are essential for businesses to thrive in the competitive market, as evidenced by successful transformations of various operators [5]

转自：前瞻产业研究院 行业主要上市公司：万集科技(300552.SZ)、北京君正(300223.SZ)、有研硅(688432.SH)、华大九天 (301269.SZ)、赛微电子(300456.SZ) 本文核心数据：集成电路产量;产业规模;产业政策;产业投融资情况 1、北京市集成电路特色产业政策环境 ——北京市集成电路特色产业政策数统计 截至2025年5月21日，北京市集成电路产业政策共有464条。2016-2024年，北京市集成电路特色产业政策数 量呈现波动的趋势，2022年为北京市集成电路特色产业政策数量的峰值，高达71个。2024年北京市集成电路 特色产业政策数量为2个，2025年1-5月，北京市集成电路特色产业政策数量为0个。 注：查询时间截至2025年5月20日，下不赘叙。 ——北京市集成电路特色产业重点政策梳理 近年来，北京市通过明确的产业规划和全方位的支持政策，致力于将集成电路产业打造成具有国际竞争力的 产业集群。在产业规划方面，北京市注重创新平台建设、集成电路设计、制造和装备的协同发展，重点布局 北京经济技术开发区、海淀区和顺义区，力争到2025年实现营业收入3000亿元。在支持政策方面，北京市 ...

Group 1 - TQP Research is led by a Certified Public Accountant (CPA) with experience in structured finance, capital markets, and credit risk [1] - The investment approach is value-oriented, focusing on identifying businesses that align with long-term success criteria taught by notable investors like Warren Buffett and Charlie Munger [1] - The primary focus is on micro-cap and small-cap investment opportunities across all sectors [1] Group 2 - TQP Research actively engages with the community and encourages questions or ideas from members [1]

UK launches £500 package to support diverse, underrepresented investors and founders | TechCrunch https://t.co/82vp9HEF7E ...

Group 1 - The AI landscape is evolving from basic single-model applications to complex multi-agent systems that resemble human organizational structures [1] - Companies are increasingly utilizing multiple AI systems rather than relying on a single AI to perform all tasks [1] Group 2 - The focus is on long/short equity strategies, emphasizing deep fundamental analysis to identify undervalued stocks for long positions and overvalued stocks for short positions in global equity markets [1] - Detailed financial models are constructed using discounted cash flow (DCF), relative valuation, and scenario analysis to assess company fundamentals, growth potential, and risks [1] - High-conviction investment recommendations are delivered through comprehensive research, contributing to alpha generation for the fund [1] - Market trends, sector dynamics, and macroeconomic factors are monitored to adjust strategies and optimize portfolio performance in real time [1] - Collaboration with the Portfolio Manager is essential for sizing positions, managing risk exposure, and addressing challenges such as short squeezes or market volatility [1]

Core Viewpoint - The company demonstrates growth through effective operational management, despite having lower revenue compared to competitors, and possesses a business model that ensures financial sustainability [1]. Investment Approach - The analysis follows a triangulation approach involving valuation by multiples, discounted cash flow (DCF), and dividend yield, focusing on Consumer Discretionary and Consumer Staples sectors [1]. - Emphasis is placed on companies with smaller capitalization and low institutional coverage, which present greater potential for asymmetries and alpha generation [1]. - The investment philosophy integrates income and value investing strategies, requiring a sufficient margin of safety in multiples and projected cash flow [1]. Dividend Yield - Dividend yield is considered a crucial element for generating returns and serves as a risk mitigation criterion, particularly for low coverage stocks [1]. Analytical Methodology - The analysis is grounded in a bottom-up approach, concentrating on operational fundamentals, execution history, and sustainable growth drivers [1]. - In-depth, rational, data-driven analyses are produced to support informed and independent investment decisions [1].

SIX’s Worldline stake has turned into a millstone around the bourse’s neck, with the exchange likely facing a third writedown in as many years following the recent collapse in Worldline’s share price https://t.co/Uh7iyS5B6T ...

Core Insights - Rhythm Pharmaceuticals presented new data on acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025), highlighting the efficacy of setmelanotide and bivamelagon in reducing body mass index (BMI) in affected patients [1][2][3]. Group 1: Clinical Data and Efficacy - The Phase 2 SIGNAL trial demonstrated that bivamelagon, a daily oral MC4R agonist, achieved statistically significant and clinically meaningful reductions in BMI over 14 weeks [2]. - The Phase 3 TRANSCEND trial showed setmelanotide resulted in a -9.3% BMI reduction in the 600mg cohort, -7.7% in the 400mg cohort, and -2.7% in the 200mg cohort, with a placebo cohort showing a 2.2% increase in BMI [4][5]. - A placebo-adjusted difference of -19.8% in BMI reduction was observed across 120 participants, with significant reductions noted in various age and sex subgroups [5][6]. Group 2: Patient Impact and Future Potential - The data from the trials suggest that both bivamelagon and setmelanotide could become transformative therapeutic options for patients with acquired hypothalamic obesity, potentially establishing a new standard of care [2][4]. - Rhythm estimates that there are between 5,000 to 10,000 individuals living with hypothalamic obesity in the U.S., indicating a significant patient population that could benefit from these treatments [11]. Group 3: Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead asset, setmelanotide, approved for treating obesity related to specific genetic conditions [9][12]. - The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists, indicating a commitment to expanding treatment options for patients with rare diseases [9].

Core Insights - Rhythm Pharmaceuticals presented new data on acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025), highlighting the efficacy of setmelanotide and bivamelagon in reducing body mass index (BMI) in affected patients [1][2][3] Group 1: Clinical Data and Efficacy - The Phase 3 TRANSCEND trial demonstrated significant BMI reductions with setmelanotide, showing a -9.3% reduction in the 600mg cohort, -7.7% in the 400mg cohort, and -2.7% in the 200mg cohort, while the placebo cohort experienced a 2.2% increase [4][5] - A placebo-adjusted difference of -19.8% in BMI reduction was observed across 120 participants, with significant reductions noted in various age and sex subgroups [5][6] - Bivamelagon, a daily oral MC4R agonist, also showed statistically significant BMI reductions in a Phase 2 trial, indicating its potential as a transformative treatment option for patients with acquired hypothalamic obesity [2][3] Group 2: Patient Population and Market Potential - Acquired hypothalamic obesity is a rare condition affecting an estimated 5,000 to 10,000 individuals in the U.S., with similar prevalence in Japan and the E.U. [11][10] - The condition is characterized by rapid weight gain and hyperphagia due to damage to the hypothalamic region of the brain, often following brain tumors or their treatment [10][11] - The presentations at ENDO 2025 underscore the potential for MC4R-targeted therapies to become the standard of care for this patient community if approved [2][3]